GlassScriptPhysician profile
Robert H Goo
NPI 1760473540
$6,222.36
in general payments reported to CMS, 2019-2025
43 companies · $1,902 in 2025
The $1,902 reported for 2025 was more than what 78% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $655 · 2020: $154 · 2021: $56.41 · 2022: $96.79 · 2023: $1,519 · 2024: $1,839 · 2025: $1,902.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,142 · Education: $118.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,142.24 |
| Education | $118.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,170.78 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $879.88 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Janssen Biotech, INC. | $839.77 | 2019-2025 | Tremfya, Stelara, Simponi |
| Regeneron Healthcare Solutions, INC. | $274.59 | 2023-2025 | Dupixent |
| Echosens North America, INC. | $229.49 | 2023 | Fibroscan |
| Pfizer INC. | $224.39 | 2019-2025 | |
| Celgene Corporation | $198.68 | 2022-2024 | Zeposia |
| Lilly USA, LLC | $198.21 | 2023-2025 | Omvoh |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $196.91 | 2019-2024 | Trulance, Xifaxan |
| Genzyme Corporation | $184.31 | 2022-2025 | |
| Intercept Pharmaceuticals, INC. | $174.49 | 2023-2025 | Ocaliva |
| Ferring Pharmaceuticals INC. | $142.55 | 2020-2024 | Rebyota |
| Aimmune Therapeutics, INC. | $137.37 | 2024-2025 | Zenpep, Vowst |
| Gilead Sciences, INC. | $118.74 | 2019-2024 | |
| Phathom Pharmaceuticals, INC. | $114.72 | 2025 | Voquezna |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $105.33 | 2023-2025 | Ibsrela |
| Qol Medical, LLC | $101.99 | 2019-2025 | Sucraid, Sucraid |
| Organon LLC | $98.90 | 2023-2025 | Hadlima |
| Shield Therapeutics INC | $86.14 | 2023-2024 | Accrufer |
| Amgen INC. | $78.89 | 2023-2025 | Avsola, Amjevita |
| Celltrion USA INC. | $75.18 | 2024-2025 | Vegzelma, Zymfentra |
| Alnylam Pharmaceuticals INC. | $67.72 | 2023-2024 | Givlaari |
| Shionogi INC | $50.29 | 2019-2020 | |
| Ucb, INC. | $47.31 | 2019 | |
| Braintree Laboratories, INC. | $35.57 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $34.71 | 2024 | Andexxa |
| Alexion Pharmaceuticals, INC. | $34.65 | 2019 | |
| Capsovision, INC. | $30.26 | 2024 | Capsocam Plus |
| Daiichi Sankyo INC. | $29.57 | 2019-2020 | |
| Ironwood Pharmaceuticals, INC | $28.62 | 2019 | |
| Madrigal Pharmaceuticals | $27.38 | 2025 | Rezdiffra |
| Pharmacosmos Therapeutics INC. | $23.99 | 2025 | Monoferric |
| Fresenius Kabi USA, LLC | $22.53 | 2024 | Idacio |
| Tersera Therapeutics LLC | $20.48 | 2025 | Xermelo |
| E.R. Squibb & Sons, L.L.C. | $18.97 | 2023 | Zeposia |
| Medtronic, INC. | $18.17 | 2024 | Interstim |
| Merck Sharp & Dohme LLC | $16.59 | 2023 | Dificid |
| Shire North American Group INC | $15.93 | 2019 | |
| Novo Nordisk INC | $15.35 | 2025 | Wegovy |
| Alfasigma USA, INC. | $14.82 | 2020 | |
| Nestle Healthcare Nutrition INC. | $13.77 | 2023 | |
| Concordia Pharmaceuticals INC. | $13.50 | 2019 | |
| Allergan, INC. | $10.87 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Goo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.